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INTRODUCTION 
 
 
The kidney is one of the most highly differentiated organs in the body.. 
Endocrine functions, the regulation of blood pressure and intraglomerular 
hemodynamics, solute and water transport, acid-base balance, and removal of fuel 
or drug metabolites are all accomplished by intricate mechanisms of renal 
response. Renal failure is classified into acute and chronic renal failure.  
 
Acute renal failure (ARF) is characterized by a rapid decline in glomerular 
filtration rate (GFR) over hours to days. . Retention of nitrogenous waste products, 
oliguria (urine output <400 mL/d contributing to extra cellular fluid overload), and 
electrolyte and acid-base abnormalities are frequent clinical features. (1)  
  
Chronic kidney disease (CKD) is an important, chronic, non communicable 
disease epidemic that affects the world, in. Because of the absence of a renal 
registry in India, the true magnitude of CKD/end-stage renal disease (ESRD) is 
unknown, eventhough it seems to be high. CKD is a worldwide public health 
problem and is now recognized as a common condition that is associated with an 
increased risk of cardiovascular disease and chronic renal failure (CRF).  
 
 
The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney 
Foundation (NKF) defines chronic kidney disease as either kidney damage or a 
decreased kidney glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 
for 3 or more months. Whatever the underlying etiology, the destruction of renal 
mass with irreversible sclerosis and loss of nephrons leads to a progressive decline 
in GFR (2). 
 K/DOQI published a classification of the stages of chronic kidney disease, 
 as follows:( 5) 
• Stage 1: Kidney damage with normal or increased GFR (>90 mL/min/1.73 
m2) 
• Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) 
• Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2) 
• Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) 
• Stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis) 
In stage 1 and stage 2 chronic kidney disease, GFR alone does not clinch the 
diagnosis. Other markers of kidney damage, including abnormalities in the 
composition of blood or urine or abnormalities in imaging tests, should also be 
present in establishing a diagnosis of stage 1 and stage 2 chronic kidney disease 
 
 The severity of signs and symptoms of uremia vary from patient to patient 
depending at least in part on the magnitude of the reduction in glomerular 
filtration rate and the rapidity with renal function is lost (3) 
The term chronic renal failure applies to the process of continuing significant 
irreversible reduction in nephron number, and typically corresponds to              
CKD stages 3–5. (4) 
The most important initial diagnostic step in the evaluation of a patient 
presenting with elevated serum creatinine is to distinguish newly diagnosed CKD 
from acute or sub acute renal failure because the latter two conditions may 
respond to therapy specific to the disease. Previous measurements of plasma 
creatinine concentration are particularly helpful in this regard. Normal values from 
recent months or even years suggest more acute, and hence reversible. Elevated 
plasma creatinine concentration in the past suggests that the renal disease 
represents the progression of a chronic process. Even if there is evidence of 
chronicity, there is the possibility of a superimposed acute process. Some of the 
laboratory tests and imaging studies  can be helpful. Evidence of metabolic bone 
disease with hyperphosphatemia, hypocalcaemia, and elevated PTH and bone 
alkaline phosphatase levels suggests chronicity. Normo chromic, normocytic 
anemia suggests that the process has been ongoing for some time. The finding of 
bilaterally reduced kidney size (<8.5 cm) favors CKD. Renal osteodystrophy 
strongly suggests the chronicity of renal dysfunction. 
The term end-stage renal disease (ESRD) represents a stage of CKD where 
the accumulation of toxins, fluid, and electrolytes normally excreted by the 
kidneys results in the uremia syndrome. This syndrome leads to death unless the 
toxins are removed by renal replacement therapy, using dialysis or kidney 
transplantation.  End-stage renal disease will be supplanted by the term stage 5 
CKD.    In the absence of a clinical diagnosis, renal biopsy may be the only 
recourse to establish an etiology in early-stage CKD. Once the CKD is advanced 
and the kidneys are small and scarred, there is little utility and significant risk in 
attempting to arrive at a specific diagnosis. 
 
Since, most of the patients of chronic kidney disease present only as 
CRF, the advanced of stage CKD( Stage 3,4 &5), and also present with 
various clinical features, this study on CRF is taken focusing the various 
clinical features, etiology and correlation of duration of symptoms with 
severity of renal failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
1. To study the various clinical presentations of CRF. 
 
2. To study the etiology of CRF and also their incidence. 
 
3. To study the correlation between duration of symptoms and the 
severity of CRF (stages of CRF). 
 
4. To study the prevalence of CRF in relation to age and sex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National 
Kidney Foundation (NKF) defines chronic kidney disease as either kidney damage 
or a decreased kidney glomerular filtration rate (GFR) of less than 60 
mL/min/1.73 m2 for 3 or more months. Whatever the underlying etiology, the 
destruction of renal mass with irreversible sclerosis and loss of nephrons leads to a 
progressive decline in GFR (2) 
K/DOQI published a classification of the stages of chronic kidney disease, as 
follows:  
Stage 1: Kidney damage with normal or increased GFR (>90 mL/min/1.73 m2) 
Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) 
Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2) 
Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) 
Stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis). (5) 
The term chronic renal failure applies to the process of continuing significant 
irreversible reduction in nephron number, and typically corresponds to CKD 
stages 3–5.  The term end-stage renal disease represents a stage of CKD where 
the accumulation of toxins, fluid, and electrolytes normally excreted by the 
kidneys results in the uremic syndrome. . End-stage renal disease will be 
supplanted term stage 5 CKD 
 
 Once the CKD is advanced and the kidneys are small and scarred, there is little 
utility and significant risk in attempting to arrive at a specific diagnosis The 
severity of signs and symptoms of uremia vary from patient to patient depending 
at least in part on the magnitude of the reduction in glomerular filtration rate and 
the rapidity with renal function is lost. (2) 
 
When the GFR is 20% to 50% of normal. Azotemia appears, usually associated 
with anemia and hypertension. Polyuria and nocturia occur as a result of decreased 
concentrating ability. Sudden stress (e.g., with nephrotoxins) may precipitate 
uremia. 
When the GFR is less than 20% to 25% of normal. The kidneys cannot regulate 
volume and solute composition, and patients develop edema, metabolic acidosis, 
and hypocalcemia. Overt uremia may ensue, with neurologic, gastrointestinal, and 
cardiovascular complications. When the GFR is less than 15% of normall, End-
Stage Renal Disease.where the patient cannot prolong his life without renal 
replacement  
 
 
 
 
GLOMERULAR FILTRATON RATE 
 
 In order to stage CKD, it is necessary to estimate the GFR. Two equations 
commonly used to estimate GFR and incorporate the measured plasma creatinine 
concentration, age, sex, and ethnic origin. 
 
1.Equation from the Modification of Diet in Renal Disease study (6) 
 
 
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0.203 
  
Multiply by 0.742 for women 
Multiply by 1.21 for African Americans 
 
 
2. Cockcroft-Gault equation 
 
    Estimated creatinine clearance (mL/min) = 
         (140-age) *body weight (kg) 
          
            72*Pcr (mg/dL) 
Multiply by 0.85 for women 
 
 
Clinical Manifestations of Chronic Kidney Disease (7) 
Uremia leads to disturbances in the function of virtually every organ system. 
Various clinical and laboratory manifestation of CKD is as follows, 
Fluid and electrolyte 
disturbances 
Volume expansion  
Hyponatremia  
Hyperkalemia  
 Hyperphosphatemia  
Endocrine-metabolic 
disturbances 
Secondary 
hyperparathyroidism  
Adynamic bone  
Vitamin D–deficient 
osteomalacia  
Carbohydrate resistance  
Hyperuricemia  
Hypertriglyceridemia  
Increased Lp(a) level  
Decreased high-density 
lipoprotein level  
Neuromuscular disturbances 
Fatigue  
Sleep disorders  
Headache  
Impaired mentation  
Lethargy  
Asterixis  
Muscular irritability 
Peripheral neuropathy  
Restless legs syndrome  
Myoclonus  
Seizures  
Coma  
Muscle cramps  
Myopathy  
Cardiovascular and 
pulmonary disturbances 
Arterial hypertension  
Dermatologic disturbances 
Pallor  
Hyperpigmentation  
Pruritus  
Ecchymoses  
Gastrointestinal disturbances 
Anorexia  
Nausea and vomiting  
Gastroenteritis  
Peptic ulcer  
Gastrointestinal bleeding  
Hematologic and immunologic 
disturbances 
Anemia  
Lymphocytopenia  
Bleeding diathesis  
Increased susceptibility to 
infection  
Protein-energy malnutrition  
Impaired growth and 
development  
Infertility and sexual 
dysfunction  
Amenorrhea  
α2-Microglobulin associated 
amyloidosis  
Congestive heart failure or 
pulmonary edema  
Pericarditis  
Hypertrophic or dilated 
cardiomyopathy  
Uremic lung 
 
The clinical characteristics, various factors and the disturbances of various vital 
organs of the CKD patients, will be considered. 
CARDIOVASCULAR 
 Cardiovascular events are the leading cause of death in CRF patients and 
they  occur at greater frequencies,compared to the normal population . 
Syndromes presented by uraemic patient in CVS (8) 
 
Congestive heart failure/hypervolaemia  
Ischaemic heart disease (±congestive heart failure)  
Left ventricular hypertrophy, concentric or eccentric  
Acquired valvular heart disease  
Arrhythmia  
Risk factors: 
  Hypertension, anemia, Diabetes mellitus, sympathetic over activity, 
arteriovenous fistula, hypervolaemia and secondary hyperparathyroidism. 
 
 
Left ventricular hypertrophy 
   LV hypertrophy is more frequent in early stages of chronic 
kidney disease and increases progressively, so that it is found in approximately 
70 per cent of patients starting renal replacement therapy (9) 
 
Factors involved in LV hypertrophy. (10) 
 
LV hypertrophy reduces actuarial survival in dialysis patients. According to 
echocardiographic LV hypertrophy defined as LV mitral inflow greater than 125 g/m 
2. 
Pericardial effusion: 
Pericarditis was discovered by Richard bright in 1936 and is categorized into 
ESRD and dialysis associated pericarditis (11).Pericarditis usually presents with 
chest pain (70%), malaise, weight loss, fever(90%) and a pericardial rub 
(90%).cardiac arrythymias (12) can occur in 20-25% of uremic patients. Volume 
overload may also contribute to pericardial effusion in patients with ESRD.  
 
X-ray chest PA view of renal failure patient shows pericardial effusion 
 
  
 
 
Hypertension: 
Hypertension occurs in 80% to 90% of patients with renal insufficiency.  Several 
factors contribute: 
a) Expansion of extracellular fluid volume; this may arise because of reduced 
ability of the kidney to excrete ingested sodium. 
b) Increased activity of the renin-angiotensin system is common; many 
patients with advanced renal failure have renin levels that are not 
completely suppressed by the elevated blood pressure. 
c) Dysfunction of the autonomic nervous system occurs with insensitive 
baroreceptor sensitive and with increased sympathetic tone. (13, 14). 
d) Possible diminished presence of vasodilators: there may be decreased renal 
generation of prostaglandins or of factors in the kallikrein-kinin system. 
Primary renal disease is the most common etiology of secondary hypertension. 
Conversely, hypertension is a risk factor for renal injury and ESRD. The increased 
risk associated with high blood pressure is graded, continuous, and present 
throughout the entire distribution of blood pressure above optimal. Renal risk 
appears to be more closely related to systolic than to diastolic blood pressure.  
The atherosclerotic, hypertension-related vascular lesions in the kidney 
primarily affect the preglomerular arterioles, resulting in ischemic changes in the 
glomeruli and postglomerular structures. Glomerular injury may also be a 
consequence of direct damage to the glomerular capillaries due to glomerular 
hyperperfusion. Glomerular pathology progresses to glomerulosclerosis, and 
eventually the renal tubules may also become ischemic and gradually atrophic. 
The renal lesion associated with malignant hypertension consists of fibrinoid 
necrosis of the afferent arterioles, sometimes extending into the glomerulus, and 
may result in focal necrosis of the glomerular tuft. 
 
In CKD patients with diabetes or proteinuria > 1 g per 24 h, blood pressure 
should be reduced to 125/75, if achievable without prohibitive adverse effects. Salt 
restriction and diuretics should be the first line of therapy. When volume 
management alone is not sufficient, the choice of antihypertensive agent is to be 
considered. (15) 
HEMOPOIETIC SYSTEM: 
Anemia: 
Patients with CKD almost uniformly develop a normocytic, normochromic anemia 
that tends to worsen in parallel with advancing azotemia. Anemia can develop as 
early as stage 3 CKD (eGFR, 30 to 60 ml/min.  Several factors contribute: 
a) Erythropoiesis is markedly depressed, mainly due to reduced erythropoietin 
production; in addition, there may be reduced end-organ response to 
erythropoietin with reduced heme synthesis. 
b) Red cell survival is shortened with a mild to moderate decrease in red cell 
life span, possible due to a “uremic” toxin. 
c) Blood loss is common in uremic patients, possibly secondary to abnormal 
coagulation due to decreased platelet function. 
d) Marrow space fibrosis occurs with osteitis fibrosa of secondary 
hyperparathyroidism resulting in decreased erythropoiesis. 
There was a higher incidence of cardiovascular events when  achieve a target 
hemoglobin level of 13.5 g/dl than when it was used to achieve a hemoglobin level 
of 11.3 g/dl. (16)  
 
 Correction of anemia with epoetin alfa in chronic kidney disease(17) Current 
practice is to target a hemoglobin concentration of 110 to 120 g/L. 
Peripheral blood smear may demonstrate the characteristic burr cells. (18) 
Usually the T lymphocyte population is normal, but there is a reduction in the B 
lymphocyte population .Both cellular and humoral immunity are impaired in renal 
failure. 
 
 
Abnormal Hemostasis 
Patients with later stages of CKD may have a prolonged bleeding time, decreased 
activity of platelet factor III, abnormal platelet aggregation and adhesiveness, and 
impaired prothrombin consumption.(19) Clinical manifestations include an 
increased tendency to bleeding and bruising, prolonged bleeding from surgical 
incisions, menorrhagia, and spontaneous GI bleeding.(20) 
Altered Calcium and Phosphorus Metabolism (Renal Osteodystrophy):  
a. As GFR decreases there is a slight retention of phosphorus; this phosphorus 
retention can lead to hypocalcemia, which stimulates PTH.  The latter 
causes phosphaturia, with restoration of serum phosphorus and calcium 
toward normal.  However, this occurs only at the expense of elevated serum 
PTH levels.  This cycle repeats itself in progressive renal failure with PTH 
levels increasing progressively.  Ultimately, the renal tubule can no longer 
respond to higher levels of PTH with a further decrease in phosphorus 
reabsorption.  When this occurs, hyperphosphatemia develops, 
hypocalcemia may become prominent and PTH level can increase to very 
high levels.  High PTH levels cause bone disease with severe osteitis 
fibrosa. 
  
 b) Altered vitamin D metabolism occurs secondary to decreased renal mass or 
to phosphate retention, with decreased synthesis of 1,25 (OH)2 D3. This 
deficiency leads to: 1. Diminished intestinal absorption of calcium, 2.  
decreased calcemic response of the skeleton to PTH, 3. impaired 
suppression of PTH secretion for any increase in serum calcium level, and 
4. altered collagen synthesis.  With advanced renal failure, these events can 
lead to secondary hyperparathyroidism and osteomalacia. Secondary 
hyperparathyroidism (21) is seen in almost all patients with CRF. 
c) Skeletal resistance to the calcemic action of PTH develops; thus an 
increased PTH is required to maintain serum calcium at any level. 
d) Finally, accumulation of aluminum from aluminum binding antacids may 
contribute to the bone disease.    
Target Levels for PTH and Phosphate in Chronic Kidney Disease (22) 
Disease Stage  PTH (pg/mL)  Phosphate (mg/dL 
[mmol/L])  
3 35–70 2.7–4.6 (0.87–1.49) 
4 70–110 2.7–4.6 (0.87–1.49) 
5 150–300 3.5–5.5 (1.13–1.78) 
PTH = parathyroid hormone.    
 
 Rocaltrol(or a calcitriol analog) 0.25 µg po once/day or 1 to 4 µg 2 times/wk. 
PTH levels are not corrected to normal because doing so risks precipitating 
adynamic bone disease. 
REPRODUCTION: 
Sexual function is profoundly affected in adults of both sexes in end stage renal 
disease. Upto 78% of males report impotence in severe CRF while the incidence in 
females is lower. Autonomic neuropathy and uremic polyneuropathy plays a 
important role in the erectile impotence of many uremic patients (23). In men,the 
manifestations are impotence decreased  libido,oligo or azoospermia. In 
women,they are dysfunctional uterine bleeding, cystic ovaries, amenorrhoea, 
anovulation and delayed puberty . These disorders are often reversed by renal 
transplantation, but dialysis fails to significantly improve them (24) 
 
DERMATOLOGICAL  MANIFESTATION 
Abnormalities of the skin are prevalent in progressive CKD. Anemic patients may
be pale, and those with defective hemostasis may show multiple ecchymoses.
Pruritus is quite common. YOUNG reported an incidence of 31 out of 46 to have 
pruritus (25).The causes are a) Altered sebaceous secretion b) defective sweating 
c) Altered calcium,phosphorus and parathormone levels.   In advanced CKD,
patients may become more pigmented, and this is felt to reflect the deposition of
retained pigmented metabolites, or urochromes 
A skin condition called nephrogenic fibrosing dermopathy has recently been 
reported in which progressive subcutaneous induration, especially on the arms and 
legs (26). Recent reports suggest that exposure to the magnetic resonance contrast 
agent, gadolinium, may precipitate this syndrome.  
The so-called 'half-and-half nail' is typical of uraemia.The distal portion of each 
nail bed is red, pink, or brown, occupies 20–60 per cent of the total nail length, 
and always sharply demarcated; the proximal portion has a dull whitish ground-
glass appearance (27) 
 
GASTROINTESTINAL SYSTEM: 
 The commonest symptoms are anorexia, nausea, vomiting, pain abdomen, 
distension of abdomen and hiccups. 
 Hemorrhagic gastritis was found in 52% of uremic patients. Reflux gastritis 
was found in 52% of uremic patients. (28) Reflux oesophagitis is also a common 
manifestation. 
 Upper G.I bleeding (29) in renal failure could be due to hemorrhagic 
gastritis, duodenitis or peptic ulcer. 
 Ulcerations of the submucosa of small intestine is also common in CRF (30, 
31, 32). Two cases with RF had small bowel intussusception (33) secondary to 
intramural hematoma that acted as the lead point. 
Absorption of iron is impaired accounting as an additional cause of anemia 
in RF. Several cases of isolated colonic ulcers have been reported in CRF (34). 
 Colonic obstruction usually occurs secondary to fecal impaction which is 
related to the use of aluminium hydroxide. Incidence is 1.7% of CRF patients. 
 Hypertriglyceridemia, along with hypocalcemia may predispose 
pancreatitis in CRF patients. 
 A hepatic abnormality in CRF patients varies from 4.4 to 60%. (35) 
Hepatomegalies, Hepatic rub, viral hepatitis especially due to hepatitis B virus are 
the commonest abnormalities noted. 
 Ascites may occur in patients with CRF, the overall incidence being about 
5%. Another series demonstrated a 26% incidence of ascites which also includes 
that, due to hemodialysis. (36, 37). 
 Ascites is a consequence of overhydration and relative fluid overload even 
in the absence of clinically evident congestive cardiac failure and peripheral 
edema. 
 Increased capillary permeability in the peritoneal membrane in RF may also 
account for the development of ascites. The association between RF and ascites 
was first described in 1970. (38) 
LUNGS: 
 Infection is the most adverse pulmonary complication in renal failure, with 
a very high mortality and morbidiy. (39) 
 Uremic lung, a radiological finding showing a butterfly distribution in chest 
x-ray is common in renal failure (R-40). Pulmonary edema occurs as a result of 
low intravascular oncotic pressure due to hypoproteinemia. 
 Uremic pleuritis, occurs in 20% of CRF patients, may demonstrate pleural 
rub, with bilateral pleural effusions. Patients may experience a typical pleural or 
catchy pain over the affected area. 
JOINTS AND SOFT TISSUE: 
 A wide variety of rheumatic diseases can affect the patients with CRF and 
specific management of renal failure can create their own problems (R-41). They 
are bone and joint infections, crystal induced arthropathy, soft tissue calcification, 
bursitis, tendintis and osteonecrosis. One study in CRF reported an incidence of 
70% of joint complaints including simple arthralgia. 
 Hyperuricemia in CRF patients can produce periarticular calcifications seen 
to the extent of 50%. Tumoral calcinosis tendon ruptures, tendonitis, bursitis have 
also been reported in CRF patients on maintenance hemodialysis. (42). 
Neuro Muscular: 
 Peripheral neuropathy is the most common complication in CRF (43, 44, 45). It 
presents as a classical sensory motor polyneuropathy with symmetrical 
involvement of both upper and lower extremities in a glove and stocking 
distribution. The lower limbs are more involved than the upper limbs. The earliest 
clinical symptoms are termed the restless leg syndrome (46) and the restlessness is 
usually worse at nights, which is usually relieved by walking about, or taking a hot 
bath. 
 Muscle cramps; usually involve the gastrocnemius muscles and intrinsic 
muscles under the arch of the feet. These cramps usually disturb the sleep at night. 
 Burning feet syndrome, also is reported, where the soles of feet feel hot and 
painfull with a sensation of swelling (47, 48). This syndrome is produced by 
abnormal functioning of the peripheral nerves and is not a true burning sensation 
(49). Loss of position and vibration sense and also loss of ankle jerks and the knee 
jerks are the most probable and earliest signs of uremic neuropathy (50). 
 As the neuropathy worsens muscle weakness and atrophy may become 
evident. 
 Hyperparathyroidism muscle weakness is a common complication in CRF 
patients due to altered calcium metabolism. Hyperparathyroidism can also 
manifest as psychiatric or neurologic illness (51). 
 Vicale C. T (52) reported weakness or fatigability as a presenting symptom 
in 70% of CRF patients. 
 The clinical syndrome of hyperparathyroidism include weakness, easy 
fatigability, symmetric proximal weakness, lower extremities more affected, 
atrophy and hyper reflexia in the absence of clonus, corticospinal tract signs, 
bulbar weakness and fasciculations. 
 Uremic encephalopathy, may mimic a true psychiatric disorder (53, 54) like 
paranoid delusions, depression etc. 
 Seizures occur as a late event in CRF. The etiology is usually hypertension 
with diastolic BP>140mm of Hg with a cerebrovascular accident. 
 Optic nerve abnormalities like homonymous hemianopia, amaurosis, and 
visual agnosia have been reported. 
 Retinal abnormalities are often seen on fundus examinations. They are 
hemorrhages, exudates, perimacular hemorrhages & arterio – venous nippings and 
rarely papilledema. Hearing loss may occur in over 75% of cases (55). 
OCULAR:  
Intra retinal leakage of lipophilic material in lipid containing macrophages 
produce the hard exudates,which are seen in hypertention(56).Cataracts are reported 
to occur prematurely due to disturbances in calcium metabolism.   
 
OBSTRUCTIVE NEPHROPATHY: 
           Since obstructive nephropathy is common, and reversible,obstruction of the 
urinary tract should should be considered in every uremic patient,whether acute or 
chronic.  
Some common causes of obstruction are  
Within the lumen  : calculus,blood clot, tumors.    
Within the wall   :ureteric stricture,conjenital bladder neck obstruction,        
Neurogenic bladder congenital urethral valve, Pin-
hole meatus. 
PRESSURE from outside :pelvi ureteric compression due to aberrant vessels, 
Retro peritoneal fibrosis,prostatic obstruction 
,Phimosis. 
 
DRUG INDUCED NEPROPATHY 
                             Drug Induced   nephropathy is common and often  
under diagnosed.This may take the form of a glomerulopathy, or a renal 
vasculitis, or an interstitial nephritis.Analgesic nephropathy usually 
takes the form of a tubulo interstitial disease.  
Common drugs responsible for Interstitial  nephritis:-  
 
 
  ANTIBIOTICS: (-lactams, sulfonamides, quinolones, vancomycin, 
erythromycin, minocycline, rifampin, ethambutol, acyclovir) 
 
  NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, CYCLOOXYGENASE 
2 INHIBITORS 
  DIURETICS:(thiazides, furosemide, triamterene) 
  ANTICONVULSANTS: (phenytoin, phenobarbital, carbamazepine, valproic 
acid) 
  MISCELLANEOUS: (captopril, H2 receptor blockers, proton pump inhibitors, 
mesalazine, indinavir, allopurinol) 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
STUDY DESIGN:  
 This study is a prospective study conducted in Thanjavur  medical college, 
department of Internal medicine and department of Nephrology. 
  In this study patients admitted for renal failure in medical ward and 
Nephrology ward were included.  
 
SELECTION CRITERIA: 
1.  Creatinine clearance less than 60ml/min/1.73sqm body surface area. 
2. documented reduction in GFR (or) elevated renal parameters for more than 
3 months (or) Kidney size less than 8.5 cm(or) increased echogenisity (or) 
history suggestive of chronicity of renal failure    
Both sexes were included in this study. 
 
EXCLUSION CRITERIA: 
1. Creatinine clearance greater than 60ml/min/1.73sqm body surface area. 
2. Normal renal parameters within 3 months.  
 
STUDY PERIOD: 
  This study was conducted between January 2007 and October 2008 
 
 
STUDY POPULATIONS: 
 The study included 100 patients of chronic renal failure (chronic kidney 
disease stage3, 4&5).All satisfied the inclusion and exclusion criteria.  
STUDY PROTOCOL AND LABORATORY INVESTIGATIONS: 
A detailed history regarding the nature and duration of presenting symptoms 
was obtained from each patient. List of symptoms regarding urinary tract, fluid 
overload, Cardio-Respiratory, Gastro-intestinal, bleeding, skin, skeletal, neuro-
muscular and reproductive systems were enquired. 
  A thorough physical examination of the patients were performed with 
particular attention towards detecting the presence of the following (Anemia, Fluid 
overload, Hypertension, Acidosis, Pericarditis, Neurological deficits Retinopathy, 
skeletal Abnormalities, Genital (or) pelvic abnormalities causing obstruction) and 
they were also evaluated with available investigations regarding chronic kidney 
disease. 
 
Urine was examined for albumin, deposits and cast especially broad cast and GFR 
was estimated using creatinine clearance. Serum.creatinine, blood sugar and urea, 
serum electrolytes, blood calcium and phosphorus were done .X-ray chest PA 
view and ECG were taken. Ultra sound abdomen was performed for evaluating the 
size of kidneys, echo texture and other obstructive pathologies. Specific 
investigations   were performed for deserving patients. Renal biopsy was not 
performed since, once the CKD is advanced and the kidneys are small and scarred, 
there is little utility and significant risk in attempting to arrive at a specific 
diagnosis. Detailed history, examination and investigations are given in proforma 
given below:   
 
 
Patients were classified, according to the definitions given below; 
Based on the creatinine clearance patients, K/DOQI categorized patients of CKD 
in to 5 stages as follows: 
• Stage 1: Kidney damage with normal or increased GFR (>90 mL/min/1.73 
m2) 
• Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) 
• Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2) 
• Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) 
• Stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis) 
Source: National Kidney Foundation: Am J Kidney Dis 39(2 Suppl 1):S1, 2002. 
  
 
 
 
 
 
 
 
Hypertension: 
Based on the JNC 7 guidelines (2003), the blood pressure were classified as 
follows:  
 
 
 
 
 
 
 
 
 
 
Blood pressure 
measurement 
Systolic BP, in 
mmHg 
Diastolic BP,in 
mmHg 
Normal <120 and <80  
Prehypertension 120–139 Or 80–89  
Stage 1 hypertension 140–159 Or 90–99  
Stage 2 hypertension >160 Or>100 
Isolated systolic 
hypertension 
140 and  <90  
Duration of Symptoms: 
Based on the duration of symptoms, patients CRF grouped as  
Group I  - < 6 months 
Group II - 6months – 2 years 
Group III - >2yrs 
 
Contracted Kidney: 
Kidney size < 8.5 cm in length 
 
Nephrotic syndrome: 
 24 hr urinary protein more than 3.5 gm/1.73sq mt body surface area. 
 
 
Hyperkalemia: 
 Serum potassium > 5 meq/L 
 
Hyponatremia: 
 Serum sodium < 3.5meq/L 
 
Hyperlipidemia: 
 Total cholesterol > 200mg/Dl 
 
Fluid overload: 
  Presence of Facial Puffiness, Pedal edema or Anasarca 
 
Ischemic heart disease 
- ECG shows in 2 concordant leads 
 -  Q waves width > .04s or amplitude > 1/4th of the R wave 
and ECHO shows hypokinesia or akinesia of ventricular free wall 
  
 
     RESULTS AND OBSERVATION: 
  
 
The total number of CKD patients in this study was 100, which included 
STAGE 3(GFR 30-59ML/MIN)  - 5 patients 
 
STAGE 4(GFR 15-29ML/MIN)  - 61 patients 
 
STAGE 5(GFR <15ML/MIN) - 34 patients 
 
 
 
THIS PIE CHART SHOWS PERCENTAGE OF CRF PATIENT IN VARIOUS 
 
STAGES 
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This chart shows prevalence of CRF related to age and sex.. 
 
 
 
 
 
 
 
 
 
 
TABLE-1            AGE DISTRIBUTION  
 
 
  
 
 
 
 
 
 
 
From this table, the maximum no. of CRF patients is in the age group of 50-59yrs 
 
 
TABLE-2 SEX DISTRIBUTION: 
   
 
 
 
 
 
 
 
 
 
From this table, the prevalence of CKD is more common in males in the 6th decade and 
more common in females in the 5th decade. 
 
 
 
AGE TOTAL % 
<20 yrs 2 2 
20-29 2 2 
30-39 4 4 
40-49 22 22 
50-59 36 36 
60-69 30 30 
70& above 4 4 
AGE MALE FEMALE 
<20 yrs 2 0 
20-29 2 0 
30-39 4 0 
40-49 16 6 
50-59 24 12 
60-69 30 0 
70& above 2 2 
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ALYSIS OF SYMPTOMS:  
  
 
 
 
  In this study presenting symptoms were observed in the 
following order. 
 
Gastro-intestinal tract symptoms  `  (80%) 
 
Symptoms of volume overload                                      (76%) 
 
Cardio respiratory symptoms    (74%) 
 
Urinary tract  symptoms     (71%) 
 
Others like (easy fatigability, lassitude, 
Fever, blurring of vision)     (67%) 
 
Neurological symptoms     (50%) 
 
Dermatological symptoms     (45%) 
  
Musculo Skeletal symptoms     (30%) 
 
Haematological Manifestations    (21%) 
 
Reproductive Tract symptoms    (10%) 
Presenting symptoms pertaining to each system were observed as follows: 
 
I. Gastro intestinal symptoms: 
 
Anorexia was present in 66%    
Nausea and vomiting was present in 50% 
Hiccups was present in 18% 
Abdominal distention was present in 14% 
Abdominal pain was present in 8% 
Diarrhea was present in 4% 
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CHART SHOWS INCIDENCE OF VARIOUS SYMPTOMS OF 
GASTROINTESTINAL TRACT. 
 
 
 
II. Symptoms of volume overload (76%)  
 
Facial puffiness was present in 60% 
Pedal edema was present in 55% 
 
III cardio-respiratory symptoms (74%) 
 
Breathlessness was present in 60% 
Chest pain was present in 32% 
Cough with expectoration was present in 10% 
Heamoptysis was present in 4% 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. Urinary tract symptoms (71%)  
Oliguria was present in 55% 
Polyuria was present in 14% 
Nocturia was present in 6% 
Hematuria was present in 2% 
Dysuria was present in 20% 
Urgency was present in 10% 
Hesitancy was present in 6%  
Frequency was present in 4% 
Clinical Presentation of Urinary Tract Symptoms
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CHART SHOWS INCIDENCE OF VARIOUS SYMPTOMS OF URINARY 
TRACT 
 
 V Unclassified symptoms (67%), 
 
Easy fatigability was present in 60% 
Lassitude was present in 12% 
Fever was present in 6% 
Blurring of vision was present in 14%  
 
VI Neurological Symptoms (50%) 
 
Headache was present in 32% 
 Sleep disturbances was present in 8% 
 Altered sensorium was present in 8% 
 Motor weakness was present in2 % 
 Seizures was present in 6% 
 
VII. Dermatological symptoms (45%); 
 
Pruritus was present in 30 % 
Rashes was present in 3% 
Skin darkening was present in 8% 
 
VIII Musculo skeletal symptoms (30%) 
 Bone and joint pain was present in 30%    
 
  IX Hematological manifestations (21%) 
 
Malena was present in 16%   
Epistaxis was present in 7%  
  
X.  Reproductive tract symptoms (10%) 
 
Impotence was present in 6% 
Amenorrhea was present in 4% 
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ETIOLOGY OF CRF PATIENTS 
 
TABLE III:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This table shows various etiologies of CRF patients in this study 
 
 
 
 
 
S. NO. ETIOLOGY TOTAL 
1 Diabetes mellitus 28 
2 Hypertension 32 
3 Chronic glomerulonephritis 10 
4 Obstructive uropathy 8 
5 Drug induced 4 
6 ADPKD 4 
7 Alport’s syndrome 2 
8 Lupus nephritis 2 
9 Not known 10 
 
TABLE IV: 
 
This table shows distribution of various etiologies in among different stages of CKD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SL. NO. ETIOLOGY STAGE 3 STAGE 4 STAGE 5  
1 Diabetes mellitus 2 14 12 
2 Hypertension - 18 14 
3 Chronic glomerulonephritis 1 9 - 
4 Obstructive uropathy - 4 4 
5 Drug induced - 4 - 
6 ADPKD 1 3 - 
7 Alport’s syndrome - 2 - 
8 Lupus nephritis 1 1 -- 
9 Not known - 6 4 
 
TABLE V: 
 
       Regarding Kidney size, 72 CRF patients had contracted kidney (<8.5cm) and 
the remaining 28 patients had normal or large sized kidneys   in Ultrasound 
abdomen. Among them they are Diabetes, obstructive uropathy and ADPKD. 
 
SL.NO. Etiology No. of  patients 
1 Diabetes mellitus 16 
2 Obstructive uropathy 8 
3 ADPKD 4 
 Total 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRF patients with  normal or enlarged kidneys 
168
4
Diabetes mellitus
Obstructive uropathy
ADPKD
DURATION OF SYMPTOMS 
 
Duration of symptoms in relation to stages of CKD  
  
TABLE VI:- 
 
Stage of CKD < 6 months 6-24 months > 24 months 
Stage 3 (5) 4(80%) 1(20%) - 
Stage 4(61) 10(16%) 29(47%) 22(36%) 
Stage 5(34) 4(11%) 10(30%) 20(59%) 
Total(100) 18 40 42 
 
 
 
In stage 3, four patients (80%) had duration of symptoms <6 months  in stage 4, 29 
patients (47%) had duration of symptoms 6-24months, in stage 5,   20 patients 
(59%) had duration of symptoms >24months 
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TABLE V: 
 
Prevalence of Hypertension in CRF patients, based on systolic blood pressure 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
This table shows, 6 patients were normotensive and 50% patients were in stage 2 
hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
Blood pressure 
measurement Systolic, mmHg No. of  patients 
Normal <120 6 
Prehypertension 120–139 6 
Stage 1 
hypertension 140–159 34 
Stage 2 
hypertension >160 50 
Isolated systolic 
hypertension 140 4 
 
DISTRIBUTION OF BLOOD PRESSURE
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 TABLE VII:-   
Incidence of Retinopathy and Neuropathy  
 
Stage of CKD Retinopathy Peripheral Neuropathy 
Stage 3 1 - 
Stage 4 10 6 
Stage 5 14 4 
Total 25 10 
 
This table shows 25% of patients had Retinopathy and 10% patient had Peripheral 
Neuropathy, both are more common in diabetes patient.. 
 
TABLE VIII:- 
 
 
Cardiac involvement in Chronic Kidney Disease  
  
Stage of CKD Congestive cardiac Failure 
Ischemic  heart 
disease Pericarditis 
Stage 3 1 - 1 
Stage 4 13 6 3 
Stage 5 16 10 8 
Total 30 16 12 
 
This table shows various incidences of CCF, CAHD and Pericarditis in CRF patients and 
distribution of different stages.  
TABLE IX:-  
Prevalence of Hyponatremia in CRF patients. 
  
Stage of CKD Hyponatremia 
Stage 3(5) 4(80%) 
Stage 4(61) 10(16%) 
Stage 5(34) 14(41%) 
Total(100) 28 
This tables shows the prevalence of hyponatremia (serum sodium<135 mEq/dl) in 
various stages of CKD  
  
TABLE X:- 
 Prevalence of hyperkalemia in CRF patients: 
 
Stage of CKD Hyperkalemia 
Stage 3(5) 1(20%) 
Stage 4(61) 25(41%) 
Stage 5(34) 32(94%) 
Total(100) 58 
 
 
This tables shows the prevalence of Hyperkelemia (serum potassium>5 mEq/dl) in 
various stages of CKD .I n stage 5, 32 out of 34 patients (94%) had Hyperkalemia. 
  
TABLE X:- 
  
Prevalence of dyslipidemia in CKD 
 
 
Stage of CKD Total cholesterol >200 mg/dl Total cholesterol <200 mg/dl 
Stage 3 (5) 4 1 
Stage IV(61) 22 39 
Stage V(34) 14 20 
Total(100) 40 60 
 
This table shows 40% of CRF patients had hyperlipidemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
 
 
PREVALANCE 0F CRF 
 
In this study, 80% were found to be males and 20% were females. ESRD is more 
common in males (USRDS 2001; K/DOQI 2002). The incident rate in the United 
States in 1999 was 380 pmp/year in males compared to 266 pmp/year in females 
(USRDS 2001). In this study, the maximum no. of CRF patients is in the age 
group of 50-59yrs (36%). The prevalence of CKD is more common in the 6th 
decade in males and more common in the 5th decade in females. The number of 
CRF patient increase with age. Eighteen major studies suggested a faster rate of 
decline in GFR in males and the incidence increases as age advances. (K/DOQI 
2002).   
 
ETIOLOGY OF CRF   
In this study, Hypertension (32%) And Diabetes (28%) was the common causes 
for CRF. Other causes are  chronic glomerulonephritis(10%),obstructive 
uropathy(8%),chronic interstitial nephritis(4%),ADPKD(2%), Alport’s syndrome 
(2%),Lupus nephritis(2%),unknown etiology(10%).  
In this study, Diabetes, Hypertension and obstructive uropathy accounting for 58% 
of CRF patient with compare to (USRDS 2001; UK Registry 2002), the 
 Incidence of hypertension (including Reno vascular hypertension), diabetes (type 
2), and obstructive uropathy accounting for 40–60 per cent of patients with CKD  
 
 
A CRF PATIENT UNDERGOING PERITONEAL DIALYSIS 
 
 
A CRF PATIENT UNDERGOING HEMO DIALYSIS 
HYPERTENTION AND DIABETES: 
In this study, Hypertension (32%) and Diabetes (28%) were the causes for 60%of 
CRF. 
Maria Eugenia Fernandes Canziani observed, main causes of CKD were:  
Hypertension (33%)& Diabetes (27%). (57) 
In the UK, Siegenthaler observed diabetic nephropathy constitutes 19%, & 
hypertension 15%.In the US diabetic nephropathy is the cause of chronic renal 
failure even in 45%, hypertension in 27%.In Japan diabetic nephropathy 30%, 
hypertension 10%, and accounting for causes. (58) 
 
CHRONIC GLOMERULONEPHRITIS (CGN): 
     In this study, CGN accounting for 10% of patient. Whereas, in Japan chronic 
glomerulonephritis is the main reason (47%), Siegenthaler observed chronic 
glomerulonephrits 10%, Maria Eugenia et al observed glomerulonephritis (8%)  
In the U S, chronic glomerulonephritis was found in 11 %.( 58) 
  
UNKNOWN: 
Among the 10 patient, 2 patients were admitted for snake bite, which are 
asymptomatic before and found to have CRF (contracted kidney and increased 
echogenicity) at the time of admission. In the remaining there is no specific history 
or clinical manifestation to accounting for any etiology. Maria Eugenia Fernandes 
Canziani.observed 14% of patients had no etiology.    
In this study, 72% patients had contracted kidneys (size <8.5 cm) and 28 % 
patients had normal (or) large sized kidneys. Among them 28 patients, 16 patients 
were Diabetes, 8 were obstructive uropathy, and 4 were ADPKD. Considering 28 
patient of Diabetes, 12 patients had contracted kidneys (43%); remaining 16 
patients had normal (or) large sized kidneys (57%). 
 
CLINICAL PROFILE: 
 In this study, the most common presentation was, gastrointestinal tract 
symptoms (80%), among them anorexia was present in (66%) followed by nausea 
and vomiting (50%), hiccups (18%), abdominal distention (14%), abdominal pain 
(8%) and diarrhea (4%). Anorexia, nausea, vomiting and hiccups were resistant to 
medications, but improve with dialysis. Abdominal distention is mainly due to free 
fluid, but in 2% due to ureamic ileus. 
 Abdominal pain (8%) is due to gastritis, peptic ulcer and pancreatitis. 
Volume overload: 
 Facial puffiness was present in 60% and pedal edema 55%. In all the 
patients, facial puffiness is more in the early morning and it is followed by pedal 
edema during the course of time. 
 Hypertension is one of the signs of volume overload. In this study, 
hypertension was found in 88% of patients, 6% were normotensive, and 6% were 
in pre hypertension. Among 88%, 34% were in stage I and 50% were in stage II. 
  
Parfrey et al (1990) observed 7 %( 59) 
 Wadi N. Suki et al (80%) (60) Hanne douc et al (1993) 85 %( 61) 
 N. Mohandas et al (1999) 82 %( 62) 
Regarding symptoms of Cardio respiratory system (74%), Breathlessness was 
presented in 60%. Most of the times it is due to acidosis followed by LV 
dysfunction, pulmonary edema, pericardial effusion, pleural effusion, respiratory 
tract infection. Chest pain was present in 32% it is mainly due to CAHD, 
pericarditis and pleuritis. 
 
In this study, 30 patients have CCF, 16 patients have ischemic heart disease, and 
12 patients have pericarditis. Among   the 16 patients with ischemic heart 
disease,8 patients are diabetic(50%).The main cause of death in patients with CKD 
is cardiovascular catastrophe and the risk to die is in ESRD patients even 10-20 
times higher compared with general population (63,64). 
 
When kidney disease progresses CKD patients become hypertensive, have 
acquired combined hyperlipidemia and hyperhomocysteinemia, increased 
oxidative stress, and decreased physical activity and psychosocial stress. If 
patients choose to smoke, the additive risk is profound. Diabetes mellitus is a 
major risk factor for both cardiovascular disease and CKD progression (65). Finally, 
renal patients have a dramatic tendency for vascular and cardiac calcification that 
is related with hyperphosphatemia and secondary hyperparathyroidism. 
History of Urinary tract symptoms were presented in 71%.In this oliguria was 
presented in 55%’more common in ESRD patients. Polyuria(14%) was more 
common  symptom in diabetes.Dysuria(20%),urgency (10%) , Hesitancy(6%) 
were commonly presents in patients with Obstructive uropathy and urinary tract 
infections. 
  Among the Neurological symptoms (50%), Headache was the common 
symptom (32%).It usually relieves with adequate control of Blood pressure. Other 
symptoms like sleep disturbances (8%) and altered sensorium (8%) improved with 
dialysis. Among the 6 patient presented with seizure, 2 patients who were resistant 
to anti-Epileptic drugs responded with Dialysis. 
With regarding to hematological manifestations (21%), History of Malena was 
present in 16%. Boyle. J.M et al, in 1983 has reported an incidence of 20% of 
Upper G I bleed in their study as evident by UGI scopy(66)    
In this study, 98 patients have Hb <12 gm%, among them 76 patients have Hb 
between 5-10 gm%, 8 patients have Hb <5 gm%. All the 98 patients are having 
normocytic normochromic anemia. But among the 8 patient with Hb<5 gm%, 5 pt 
were having associated iron deficiency anemia (microcytic hypo chromic anemia 
and  
S Ferritin less than normal).2 Patients with Hb >12 gm% were ADPKD. Oxford 
renal unit was identified, a 100% incidence of anemia of normocytic normocromic 
type in patients with CRF (67) 
 
Anemia is an early and common complication of chronic kidney disease. 
Once end-stage kidney failure occurs, all patients are eventually affected. In the 
NHANES III (only 1% of participants with a glomerular filtration rate (GFR) > 60 
ml/min were found to suffer from anaemia . However, in a cohort of patients with 
CKD, 25% of patients with a GFR >50 ml/min had Hb <12 g/dl (68). 
 
 From the available trial evidence, in CKD patients with cardiovascular 
disease, the benefits associated with higher Hb targets (reduced seizures) are 
outweighed by the harms (increased risk of hypertension and death). (69) The 
EBPG recommend Hb values >11 g/dl, while the K/DOQI clinical practice 
guidelines and clinical practice recommendations suggest Hb levels between 11 
and 13 g/dl.  Recent trials recommend a target Hb level between 11 and 12 g/dl in 
CKD patients. (70, 71) .History of both Malena and Epistaxis were present in 2 
patients.  
Regarding Dermatological symptoms (72), 30 out of 100 patients (30%) have 
pruritus.Scott Moses M.D in 2003, have reported 25% pt have pruritus in CRF. (73) 
Balaskar et.al in 1993, have reported 60% incidence of pruritus in CRF patients 
with or without dialysis. (79)  
8 out of 100 patients had hyper pigmentation due to uremia. This is felt to reflect 
the deposition of retained pigmented metabolites, or urochromes 
 
. 
               
 
Figure shows hyper pigmentation of palm of a CRF patient 
 
 
 
 
 
 
 
In this study, 29 out of 100 patients (29%) had Half and Half nails. 
 
 
 
 
Figure shows half and half nail of a CRF patient 
 
 
            
 
 
Agarwal S k et.al 2005 had reported an incidence of 20-50 %.( 74) 
 
Lubach et al 1982, has reported incidence of 15-50% in CRF patients with or 
without dialysis. (75)  
 
 
 
 
 
 
 
 
 
 
Among the symptoms of skeletal system (30%), Bone and joint pain was 
present in 30%.Renal Osteodystrophy (ROD) was demonstrated in 8 persons. 
 
Baurqub MA, has reported an prevalence of 55.3%in patients on maintenance  
 
Dialysis. (76) 
 
U C odenisho showed that renal osteodystrophy, demonstrable by radiography 
only 3 subjects (3.35%). (77)  
Adel Afifi has reported a prevalence of renal osteodystrophy ranging from 24.4% 
to 63 %. (78) 
 
  Regarding the duration of symptoms: 
 
In stage 3, four patients (80%) had duration of symptoms <6 months 
  One patient (20%) had duration of symptoms 6-24months 
            No patient had duration of symptoms >24months 
 
In stage 4,  
10 patients (16%) had duration of symptoms <6 months 
  29 patients (47%) had duration of symptoms 6-24months 
           22 patients (36%) had duration of symptoms >24months 
 
 
In stage 5,  
4 patients (11%) had duration of symptoms <6 months 
  10 patients (30%) had duration of symptoms 6-24months 
           20 patients (59%) had duration of symptoms >24months 
From this information, it is known that if the patients had more duration of 
symptoms, they are in more advanced stages of renal failure and vice versa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
This study on CRF shows the following,  
1. The prevalence of CRF is more common in males (80%),compared to 
females (20%) 
2. CRF occurs even in the second decade (2%) and as the age advances the 
incidence is also increasing and reaches peak in the fifth decade (36.6%) 
3. The initial presentation of CRF is more common in stage 4 of CKD (61%) 
compare to stage 5 – ESRD (34%). Stage 3 was the least (5%) 
4. The most common clinical presentation was Gastro intestinal symptoms 
(80%) compared to symptoms of volume overload (76%) 
5. Among the various symptoms of CRF, anorexia was the leading one(66%) 
6. Normal Blood Pressure was found in 6% of cases 
7. Seizures was the only initial presentation in few cases(2%) 
8. Rarely CRF is even asymptomatic (2%) 
9. Anemia was observed in 98%, CCF in 30%, Pericarditis in 12% and 
dyslipidemia in 40% of patients. 
10. Hypertension and DM were the common etiology (32%) & (28%) 
respectively. The remaining causes were Chronic Glomerulonephritis 
(10%) as well as CRF of Unknown Etiology (10%). Obstructive uropathy is 
found to be 8%. Drug induced CRF was 4%. 
11. USG abdomen showed normal or enlarged sized kidney in 28% of cases 
12. Renal scan study showed, normal or enlarged kidney in more than 50% of 
cases of Diabetes with CRF. 
13. Duration of symptoms directly correlates with the severity of Renal failure 
(stage 3 to 5) 
14. The best way to prevent the emergence of CRF is by strict control of the 
Blood Pressure in Hypertensives and Blood sugar in Diabetics. 
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PROFORMA 
 
THANJAVUR MEDICAL COLLEGE 
A STUDY OF CHRONIC KIDNEY DISEASE (stage3, 4&5) 
 
NAME    AGE     SEX 
ADDRESS    OCCUPATION   INCOME 
     I.P NO:    DATE:  
 
PRESENTING COMPLAINTS                                                       DURATION                             
 
 
URINARY TRACT SYMPTOMS: 
(a)Oliguria  
(b)polyuria  
(c)nocturia 
(d)hematuria 
(e)dysuria 
(f)Urgency 
(g)Hesitency  
(h)Frequency 
 
SYMPTOMS OF VOLUME OVERLOAD: 
(a)Pedal Edema 
(b)Facial Puffiness  
 
 
CARDIO-RESPIRATORY SYMPTOMS: 
(a)Breathlessness 
(b)Chest pain 
(c)Cough with expectoration. 
(d)Haemoptysis. 
 
GASTRO-INTESTINAL SYMPTOMS: 
(a)Anorexia  
(b)Nausea and vomiting 
(c)Diarrhoea 
(d)Abdominal pain. 
(e)Hiccups 
(f)Abdominal distention. 
 
HAEMATOLOGICAL SYMPTOMS: 
(a)Epistaxis 
(b)Malena 
DERMATOLOGICAL SYMPTOMS: 
(a)Pruritus 
(b)Rashes 
(c)Skin darkening. 
 
MUSCULO-SKELETAL SYMPTOMS: 
 (a)Bone and joint pain  
 (b)Deformities 
 (c)Fractures 
 
NEUROLOGICAL SYMPTOMS: 
 (a)Headache 
 (b)Sleep disturbances 
 (c)Altered sensorium 
 (d)Paralysis 
 (e)Seizures 
 
REPRODUCTIVE TRACT SYMPTOMS: 
 (a)Impotence 
 (b)Infertility 
 (c)Amenorrhoea 
 
OTHERS 
 (a)Easy fatigability 
 (b)Lassitude 
 (c)Fever 
 (d)Blurring of vision 
     
PAST HISTORY  
          
Hypertension       Proteinuria 
 
Diabetes mellitus     Hematuria 
     
Tuberculosis      CAD 
 
U.T.I       Drugs/chemicals 
 
Jaundice      Calculi    
 
 
 
PERSONAL HISTORY 
 
 
Tobacco      Analgesics 
 
Alcohol      Indigenous medicines 
 
Smoker 
 
 
FAMILY HISTORY  
 
Diabetes mellitus 
 
Hypertension 
 
Deafness 
        
Hematuria    
  
 GENERAL EXAMINATION 
 
Anemia       Jaundice 
 
Build                   Edema 
 
Lymph nodes                  Skin   
 
          
VITALS 
 
Temp   
 
Pulse         Blood pressure 
 
JVP                              Respiration 
 
 
 
CARDIOVASCULAR SYSTEM 
 
Heart sounds       Apex beat  
 
Pericardial rub      Murmurs  
 
 
 
 
RESPIRATORY SYSTEM  
 
Breath sounds      Added sounds 
           
 
 
ABDOMEN 
 
Free fluid       Organomegaly 
 
Renal angle tenderness     Bruit 
 
Genitalia 
 
 
NERVOUS SYSTEM 
 
Higher mental functions     Cranial nerves 
 
Spinal motor system      Sensory system 
 
Reflexes       Fundus 
 
INVESTIGATIONS 
 
URINE ANALYSIS 
       
Urine albumin 
 
Urine sugar 
 
Urine deposits (casts 
 
24hr urinary protein 
 
Urine c/s 
 
CREATININE CLEARANCE (ml/min) 
 
 
BIOCHEMICAL ANALYSIS 
 
Blood urea  
 
Serum creatinine 
 
Serum electrolytes:       Na+                           k+ 
 
Blood sugar:                      F                                PP 
 
Plasma acetone 
 
Serum calcium 
       
Serum cholesterol 
 
Serum phosphorus 
 
 
HAEMATOLOGICAL INVESTIGATIONS 
 
Hb:       gm%       RBC’S 
 
TC:                          DC: 
 
PLATELET 
PERIPHERAL SMEAR 
 
X-RAY CHEST PA VIEW 
       
USG ABDOMEN  
 
ECG 
 
ECHO 
 
OTHER INVESTIGATIONS: 
 
 
 
